Security
Yarrow Bioscience, Inc. Common Stock · YARW
YARWNASDAQCommon stockCurrentCIK 1566044Updated Nov 2, 2026
Name history
VYNE Therapeutics Inc. · through Jul 24, 2026Menlo Therapeutics Inc. · through Sep 2, 2020Menlo Therapeutics, Inc. · through Jan 31, 2018Tigercat Pharma, Inc. · through Jan 7, 2013
YARW price & chart
Loading TradingView…
NASDAQ:YARW on TradingView ↗About the company
Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company is developing YB-101, a potentially first-in-class anti-thyroid stimulating hormone receptor (“TSHR”) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both GD and TED. For more information, visit www.yarrowbioscience.com.
In the news
No coverage from other publishers is available.
Recent filings
Entry into a Material Definitive Agreement
Items 1.01, 9.01
424B5 filing
424B5 filing
Other Events
Items 8.01, 9.01
EFFECT filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2024 | Q3 2023 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 76,198,000Source | 19,267,000Source | 23,604,000Source | 44,718,000Source | 86,648,000Source | 25,873,000Source | 56,423,000Source | 91,676,000Source | 30,160,000Source | 66,905,000Source | 97,685,000Source | 40,758,000Source |
| Property, Plant and Equipment, NetUSD | — | — | 78,000Source | 102,000Source | — | 84,000Source | 107,000Source | — | 90,000Source | 113,000Source | — | 0Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 16,272,000Source | 15,448,000Source | 22,925,000Source | 22,047,000Source | 29,609,000Source | 24,631,000Source | 28,209,000Source | 19,065,000Source | 24,027,000Source | 19,926,000Source | 30,620,000Source | 30,908,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 250,000Source | — | — | — | — | — | — | — | — | — | 173,000Source |
| Assets, CurrentUSD | 73,535,000Source | 17,511,000Source | 23,526,000Source | 44,343,000Source | 83,776,000Source | 25,789,000Source | 54,913,000Source | 90,223,000Source | 30,010,000Source | 64,437,000Source | 95,963,000Source | 38,275,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,303,000Source | 1,759,000Source | 601,000Source | 4,696,000Source | 5,629,000Source | 861,000Source | 4,641,000Source | 4,219,000Source | 1,002,000Source | 2,921,000Source | 2,656,000Source | 2,127,000Source |
| Operating Lease, Right-of-Use AssetUSD | 122,000Source | 0Source | — | 32,000Source | 151,000Source | — | 62,000Source | 180,000Source | 0Source | 93,000Source | 207,000Source | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 12,661,000Source | 7,762,000Source | 1,542,000Source | 5,836,000Source | 11,779,000Source | 1,236,000Source | 12,291,000Source | 8,306,000Source | 2,395,000Source | 14,819,000Source | 8,950,000Source | 9,345,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 1,000Source | 0Source | 0Source | 2,000Source | 1,000Source | 3,000Source | 2,000Source | 1,000Source | 3,000Source | 1,000Source | 1,000Source | 0Source |
| Additional Paid in CapitalUSD | 782,650,000Source | 696,653,000Source | 786,307,000Source | 784,418,000Source | 781,917,000Source | 785,872,000Source | 783,911,000Source | 781,024,000Source | 785,413,000Source | 783,235,000Source | 780,044,000Source | 693,937,000Source |
| Retained Earnings (Accumulated Deficit)USD | -719,148,000Source | -685,148,000Source | -764,245,000Source | -745,536,000Source | -706,991,000Source | -761,238,000Source | -739,781,000Source | -697,585,000Source | -757,653,000Source | -731,170,000Source | -691,336,000Source | -662,735,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 34,000Source | — | 0Source | -2,000Source | -58,000Source | 0Source | 0Source | -70,000Source | 2,000Source | 20,000Source | 26,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 63,537,000Source | 11,505,000Source | 22,062,000Source | 38,882,000Source | 74,869,000Source | 24,637,000Source | 44,132,000Source | 83,370,000Source | 27,765,000Source | 52,086,000Source | 88,735,000Source | 31,202,000Source |
| Liabilities and EquityUSD | 76,198,000Source | 19,267,000Source | 23,604,000Source | 44,718,000Source | 86,648,000Source | 25,873,000Source | 56,423,000Source | 91,676,000Source | 30,160,000Source | 66,905,000Source | 97,685,000Source | 40,758,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 12,661,000Source | 6,449,000Source | 1,542,000Source | 5,836,000Source | 11,754,000Source | 1,236,000Source | 12,291,000Source | 6,930,000Source | 2,395,000Source | 14,819,000Source | 7,538,000Source | — |
| Operating Lease, Liability, CurrentUSD | 123,000Source | — | — | 25,000Source | 120,000Source | — | 63,000Source | 117,000Source | 0Source | 99,000Source | 115,000Source | 0Source |
| Operating Lease, Liability, NoncurrentUSD | 0Source | — | — | — | 25,000Source | — | — | 63,000Source | — | 0Source | 99,000Source | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 6,168,000Source | 4,452,000Source | 815,000Source | 3,578,000Source | 5,069,000Source | 889,000Source | 6,858,000Source | 3,642,000Source | 941,000Source | 9,272,000Source | 4,119,000Source | 4,381,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 31,000,000Source |
| Long-term DebtUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Short-term InvestmentsUSD | 53,913,000Source | — | — | 17,600,000Source | 48,492,000Source | 297,000Source | 22,063,000Source | 66,885,000Source | 4,981,000Source | 41,590,000Source | 62,633,000Source | — |
cash flow · annual statements
| Line item | Q4 2024 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | 6,000Source | 6,000Source | 0Source | 23,000Source | 4,000Source | 0Source | 72,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | 474,000Source | 763,000Source | 985,000Source | 2,308,000Source | 3,303,000Source | 3,305,000Source | 4,297,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -97,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | -4,081,000Source | -11,461,000Source | -7,981,000Source | -33,124,000Source | -33,972,000Source | -25,341,000Source | -29,200,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | 4,700,000Source | 19,831,000Source | -3,569,000Source | 37,368,000Source | 23,365,000Source | -57,354,000Source | 15,667,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | -15,000Source | -87,000Source | -5,000Source | -143,000Source | -141,000Source | 82,394,000Source | 1,653,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | 604,000Source | 8,283,000Source | -11,555,000Source | 4,101,000Source | -10,748,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | 16,319,000Source | 22,925,000Source | 22,047,000Source | 29,655,000Source | 24,631,000Source | 28,209,000Source | 19,119,000Source | 24,027,000Source | 19,926,000Source | 30,674,000Source | 30,975,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | 734,000Source | 436,000Source | 529,000Source | 885,000Source | 474,000Source | 763,000Source | 985,000Source | 2,308,000Source | 3,303,000Source | 3,305,000Source | 4,297,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 31,000,000Source |
| DepreciationUSD | — | — | 6,000Source | 12,000Source | 0Source | 6,000Source | 6,000Source | 0Source | 23,000Source | 4,000Source | 0Source | — |
| Gain (Loss) on Disposition of BusinessUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 12,918,000Source |
| General and Administrative ExpenseUSD | — | 2,964,000Source | 2,411,000Source | 2,730,000Source | 3,288,000Source | 3,085,000Source | 3,275,000Source | 3,770,000Source | 11,082,000Source | 13,192,000Source | 13,375,000Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | -12,157,000Source | -2,899,000Source | -5,747,000Source | -9,395,000Source | -3,585,000Source | -8,603,000Source | -6,241,000Source | -26,736,000Source | -39,807,000Source | -27,872,000Source | -33,945,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | 0Source | -108,000Source | -8,000Source | -11,000Source | 0Source | -8,000Source | -8,000Source | 253,000Source | -27,000Source | -580,000Source | 10,735,000Source |
| Income Tax Expense (Benefit)USD | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 4,000Source | 4,000Source | 0Source | 13,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | -12,157,000Source | -3,007,000Source | -5,755,000Source | -9,406,000Source | -3,585,000Source | -8,611,000Source | -6,249,000Source | -26,483,000Source | -39,834,000Source | -28,452,000Source | -23,210,000Source |
| Other Nonoperating Income (Expense)USD | — | 934,000Source | 203,000Source | 1,795,000Source | 1,001,000Source | 231,000Source | 594,000Source | 1,139,000Source | 3,017,000Source | 3,834,000Source | 1,386,000Source | 363,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 0Source | — | — | — | 1,470,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | 0Source | 1,000Source | 0Source | 1,000Source | -1,000Source | — |
income statement · annual statements
| Line item | Q4 2024 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | 121,000Source | 97,000Source | 69,000Source | 198,000Source | 86,000Source | 202,000Source | 98,000Source | 570,000Source | 501,000Source | 424,000Source | 477,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 16,387,000Source |
| Operating Income (Loss)USD | — | -13,091,000Source | -3,102,000Source | -7,542,000Source | -10,396,000Source | -3,816,000Source | -9,197,000Source | -7,380,000Source | -29,749,000Source | -43,637,000Source | -29,258,000Source | -34,295,000Source |
| Other Nonoperating Income (Expense)USD | — | 934,000Source | 203,000Source | 1,795,000Source | 1,001,000Source | 231,000Source | 594,000Source | 1,139,000Source | 3,017,000Source | 3,834,000Source | 1,386,000Source | 363,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | -12,157,000Source | -2,899,000Source | -5,747,000Source | -9,395,000Source | -3,585,000Source | -8,603,000Source | -6,241,000Source | -26,732,000Source | -39,803,000Source | -27,872,000Source | -33,932,000Source |
| Income Tax Expense (Benefit)USD | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 4,000Source | 4,000Source | 0Source | 13,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | -12,157,000Source | -3,007,000Source | -5,755,000Source | -9,406,000Source | -3,585,000Source | -8,611,000Source | -6,249,000Source | -26,483,000Source | -39,834,000Source | -28,452,000Source | -23,210,000Source |
| Earnings Per Share, BasicUSD per share | — | -0.29Source | -3.51Source | -6.73Source | -0.22Source | -0.08Source | -0.2Source | -0.15Source | -0.62Source | -0.93Source | -2.78Source | -7.28Source |
| Earnings Per Share, DilutedUSD per share | — | -0.29Source | -3.51Source | -6.73Source | -0.22Source | -0.08Source | -0.2Source | -0.15Source | -0.62Source | -0.93Source | -2.78Source | -7.28Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | 42,587,000Source | 858,000Source | 855,000Source | 42,586,000Source | 42,768,000Source | 42,673,000Source | 42,581,000Source | 42,768,000Source | 42,589,000Source | 10,273,000Source | 3,186,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | 42,587,000Source | 858,000Source | 855,000Source | 42,586,000Source | 42,768,000Source | 42,673,000Source | 42,581,000Source | 42,768,000Source | 42,589,000Source | 10,273,000Source | 3,186,000Source |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | 13,212,000Source | 3,199,000Source | 7,611,000Source | 10,594,000Source | 3,902,000Source | 9,399,000Source | 7,478,000Source | 30,319,000Source | 44,138,000Source | 29,682,000Source | 34,772,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 4,000Source | 4,000Source | 0Source | 13,000Source |
| General and Administrative ExpenseUSD | — | 2,964,000Source | 2,411,000Source | 2,730,000Source | 3,288,000Source | 3,085,000Source | 3,275,000Source | 3,770,000Source | 11,082,000Source | 13,192,000Source | 13,375,000Source | — |
| Income (Loss) Attributable to Parent, before TaxUSD | — | — | — | — | — | — | — | — | -26,478,000Source | -39,830,000Source | -28,452,000Source | 23,193,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | -12,157,000Source | -2,899,000Source | -5,747,000Source | -9,395,000Source | -3,585,000Source | -8,603,000Source | -6,241,000Source | -26,736,000Source | -39,807,000Source | -27,872,000Source | -33,945,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | -0.29Source | -3.38Source | -6.72Source | -0.22Source | -0.08Source | -0.2Source | -0.15Source | -0.63Source | -0.93Source | -2.72Source | -10.65Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | -0.29Source | -3.38Source | -6.72Source | -0.22Source | -0.08Source | -0.2Source | -0.15Source | -0.63Source | -0.93Source | -2.72Source | -10.65Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | 0Source | -108,000Source | -8,000Source | -11,000Source | 0Source | -8,000Source | -8,000Source | 253,000Source | -27,000Source | -580,000Source | 10,735,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Research and Development ExpenseUSD | — | 10,248,000Source | 788,000Source | 4,881,000Source | 7,306,000Source | 817,000Source | 6,124,000Source | 3,708,000Source | 19,237,000Source | 30,946,000Source | 16,307,000Source | 18,385,000Source |
Offerings
Registration 333-277609
Registration 333-294804
Filing attachments
tm2624937d1_ex99-1.htm · 8-K · 2026-09-10
EX-99.1 2 tm2624937d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 1 Bringing life into balance Yarrow Bioscience Overview September 2026 2 Disclaimers The information contained in this presentation has been prepared by Yarrow Bioscience, Inc. and its affiliates (“Yarrow” or t he “Company”) and contains information pertaining to the business and operations of the Company. The information contained in this presentation: (a) is provided as of the date hereof, is subject to change without notice, and…
Read attachment ↗tm2624937d1_ex99-2.htm · 8-K · 2026-09-10
EX-99.2 3 tm2624937d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 PART I, ITEM 1. BUSINESS Overview Yarrow Bioscience, Inc. (“Yarrow”) is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. Yarrow’s lead product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor (“TSHR”), which Yarrow plans to develop for the treatment of Graves’ disease (“GD”) and t…
Read attachment ↗ex991_1.htm · SCHEDULE 13G/A · 2026-08-07
EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned …
Read attachment ↗ex991_1.htm · SCHEDULE 13G · 2026-08-04
EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned …
Read attachment ↗tm2621655d1_ex99-1.htm · SCHEDULE 13G · 2026-07-30
EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13(d)-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the co…
Read attachment ↗tm2620687d3_ex4-1.htm · 8-K · 2026-07-28
EX-4.1 7 tm2620687d3_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 Execution Version THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO …
Read attachment ↗